This week we are welcoming Argyris Chlorogiannis as a Research Analyst to our Modelling, Access, and Strategy team in Stockholm.
Argyris is a Pharmacist with a Master’s degree in Health Economics, Policy, and Management from […]
In an era where healthcare decisions are becoming increasingly complex, the ISPOR Value Flower offers a refreshing perspective on how we assess the true value of medical interventions.
What is it?
The Value Flower is a conceptual model that expands beyond traditional […]
In just a few days, Quantify’s Johan Liseth Hansen and Oskar Ström will be heading to the ESMO – European Society for Medical Oncology Congress 2024 to present some of Quantify’s recent oncology research […]
Quantify Research is pleased to announce a new strategic partnership with Inka Health, a leader in health outcomes research providing advanced analytical solutions that support evidence-based decision-making. This […]
Quantify Research is excited to host its next morning meeting on 9 October in Copenhagen! Denmark has unique registry data, but there is uncertainty about how to best use it to create quality evidence for decision-making. In this session, […]
Although we didn’t win the obscenely difficult quiz night on Tuesday (there wasn’t even one question about health economics or epidemiology!), the Quantify team did score highest in team spirit.
Jessica Young from Quantify Research’s Stockholm office had a fantastic time at last week’s International Society for Pharmacoepidemiology‘s annual meeting, reconnecting with colleagues, meeting new faces, and diving into engaging discussions around the role […]
Last week the team came together to give the office plants some much needed TLC.
Turns out there are a fair few green fingers at Quantify!
Whilst we might not be adding gardening to […]
Quantify’s Mathias Lilja and Johan Mesterton are co-authors on a new study on cytarabine dosing for treating secondary and high-risk AML using a synthetic control arm study design.
Since 1980’s, the standard treatment of acute myeloid leukemia (AML) is cytarabine infusion […]
Our capabilities have significantly expanded, allowing us to offer comprehensive support for your Finnish data and access needs.
As the leading provider of Nordic RWE and market access services, we’ve strengthened our Finnish presence to deliver:
▪ End-to-end RWE including patient-level data […]